Axsome Therapeutics (AXSM) Q1 2023: Availity Prescriptions Surge 298%, Fueling Commercial Ramp
Axsome Therapeutics delivered a breakout quarter with Availity prescription growth of nearly 300%, signaling rapid adoption and a strong launch trajectory. Synosy maintained growth despite market headwinds and a distribution model shift, while the company advanced multiple late-stage pipeline programs. Management’s focus on commercial execution and pipeline progression sets up a pivotal 12-18 months as Axsome aims to expand its CNS portfolio and achieve cash flow positivity.
Summary
- Commercial Launch Momentum: Availity’s rapid prescription ramp and expanding prescriber base highlight robust early demand.
- Pipeline Execution: Multiple late-stage programs are progressing toward key data readouts and NDA filings.
- Strategic Capitalization: Expanded cash runway and out-licensing support continued growth and operational flexibility.
Business Overview
Axsome Therapeutics is a CNS-focused biopharmaceutical company that develops and commercializes novel therapies for brain disorders. The company’s revenue model combines product sales from its two marketed brands—Availity, a differentiated antidepressant for major depressive disorder (MDD), and Synosy, a wake-promoting agent for excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) and narcolepsy—with out-licensing and royalty income from international partners. Its late-stage pipeline targets additional CNS indications including migraine, narcolepsy, fibromyalgia, Alzheimer’s agitation, and smoking cessation.
Performance Analysis
Axsome’s Q1 2023 marked a commercial inflection point, with total net product sales of $28.8 million driven by Availity’s first full quarter on the market and steady Synosy demand. Availity prescriptions soared, with 31,000 scripts reported in the quarter, up 298% sequentially, and the number of unique prescribers tripled to over 6,000. This rapid expansion underscores strong uptake among both early adopters and new prescribers, supported by broad payer coverage and robust field force engagement.
Synosy delivered 13% year-over-year US prescription growth despite a flat EDS market and a $3.3 million sales impact from a distribution model change. International out-licensing to PharmaNovia contributed incremental royalty and licensing revenue, diversifying Axsome’s revenue base beyond the US. Operating expenses rose sharply, reflecting commercial build-out and R&D investment, but were offset by new product revenue and out-licensing proceeds, narrowing the net loss from the prior year.
- Prescription Ramp Drives Revenue: Availity’s 298% script growth and expanding HCP reach underpin the quarter’s sales acceleration.
- Distribution Model Shift Impacts Synosy: A $3.3 million headwind from US channel transition masked underlying prescription strength.
- Cash Position Strengthened: Cash and equivalents rose to $246.5 million, bolstered by licensing proceeds and a larger, lower-cost loan facility.
With both products addressing large, underserved CNS markets and payer access tracking to plan, Axsome is building a foundation for multi-product growth and future profitability.
Executive Commentary
"We saw strong performance in all areas of our business in the first quarter, which included advancing the commercialization of Availity and Synosy, progressing our late stage product pipeline, out-licensing XUS rights for Synosy, and strengthening our financial position."
Dr. Ariel Tabuto, Chief Executive Officer
"We believe that our current cash balance, along with the remaining committed capital from the $350 million term loan facility with Hercules Capital, is sufficient to fund anticipated operations into cash flow positivity based on our current operating plan."
Nick Peavy, Chief Financial Officer
Strategic Positioning
1. Availity Launch Execution
Availity, Axsome’s differentiated MDD therapy, is seeing rapid adoption among physicians and patients, with refill rates indicating early persistence and compliance. The company’s omnichannel marketing and a focused field force have reached over 22,000 HCPs, while payer coverage is tracking ahead of typical launch curves, especially in commercial and government channels.
2. Synosy Market Expansion and Out-Licensing
Synosy continues to capture share in EDS despite market stagnation, supported by a relaunch campaign and broad payer access. The out-licensing of ex-US rights to PharmaNovia provides upfront and royalty revenue, expanding the product’s geographic reach and de-risking international commercialization.
3. R&D Pipeline Advancement
Axsome’s late-stage pipeline is advancing on multiple fronts, with pivotal data readouts and NDA filings expected for AXS-07 (migraine), AXS-12 (narcolepsy), and AXS-14 (fibromyalgia) over the next 12-18 months. The company is also progressing phase 3 and phase 2/3 trials in ADHD and smoking cessation, aiming to broaden its CNS portfolio and address additional high-unmet-need indications.
4. Capital and Cost Discipline
Management has secured a larger, lower-cost credit facility and is leveraging out-licensing to extend the cash runway, supporting both commercial scaling and clinical development without near-term dilution.
Key Considerations
Axsome’s Q1 performance reflects a well-orchestrated commercial launch, disciplined capital management, and a robust late-stage pipeline. The next year will test the company’s ability to sustain Availity’s momentum, execute on Synosy’s relaunch, and deliver on pivotal pipeline milestones.
Key Considerations:
- Launch Trajectory Validated: Early Availity uptake and refill trends support long-term potential if payer access continues to expand.
- Pipeline Readouts as Catalysts: Multiple pivotal trials will shape the future commercial footprint and valuation.
- Out-Licensing Diversifies Revenue: International partnerships provide non-dilutive capital and validate Synosy’s global potential.
- Expense Base Rising: SG&A and R&D costs are elevated due to launch and pipeline activity, but are expected to moderate as scale is achieved.
Risks
Axsome faces execution risk as it scales commercial operations and manages multiple late-stage programs in parallel. Delays or negative outcomes in pivotal trials could impact both near-term growth and long-term portfolio value. Payer access and gross-to-net dynamics remain volatile, particularly as Availity moves up the treatment line and as Synosy’s channel transitions normalize. The company’s reliance on a small number of products and a concentrated prescriber base also heightens operational risk.
Forward Outlook
For Q2 2023, Axsome expects:
- Continued Availity prescription growth as payer coverage expands and prescriber base broadens.
- Steady Synosy performance with normalization of distribution and incremental international royalties.
For full-year 2023, management did not provide explicit revenue guidance, citing early launch dynamics and evolving payer access, but reiterated:
- Cash runway into cash flow positivity under current plans.
Management highlighted several factors that will shape upcoming quarters:
- Additional formulary decisions for Availity expected in the coming months.
- Key pipeline data readouts and NDA filings anticipated over the next 12-18 months.
Takeaways
Axsome is executing on a dual commercial and R&D strategy, with Availity’s launch outpacing early expectations and Synosy’s relaunch stabilizing. The next year will be pivotal as late-stage pipeline programs mature and new data shape the company’s CNS portfolio trajectory.
- Commercial Momentum: Availity’s rapid script growth and prescriber expansion position it as a potential new standard in MDD if payer access and persistence trends hold.
- Pipeline Depth: Multiple late-stage assets provide diversification, but also concentrate execution risk around upcoming data and regulatory milestones.
- Watch for Gross-to-Net and Access Trends: Payer dynamics and channel mix will be critical to sustaining the current growth trajectory and margin structure.
Conclusion
Axsome’s Q1 2023 marks a turning point, with Availity’s strong launch and Synosy’s resilience validating the company’s commercial model. The next 12-18 months will determine whether Axsome can translate pipeline advances into durable multi-product growth and move toward sustainable profitability.
Industry Read-Through
Axsome’s success with Availity’s rapid launch and Synosy’s international out-licensing offers a blueprint for CNS-focused biopharma scaling new therapies in large, underserved indications. The company’s disciplined approach to payer access, omnichannel HCP engagement, and global partnering reflects best practices for maximizing launch velocity and geographic reach in specialty pharma. For peers, the importance of early persistence data, payer alignment, and flexible capital strategies is underscored by Axsome’s trajectory. The CNS category remains highly competitive, but Axsome’s execution signals that differentiated mechanisms and focused commercial investment can unlock robust growth even in crowded markets.